These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 34918639)

  • 21. Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy.
    Chen Q; Zhang W; Fu Q; Liang X; Liu W; Xiao S; Lu H
    Am J Gastroenterol; 2016 Dec; 111(12):1736-1742. PubMed ID: 27670603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
    Liou JM; Jiang XT; Chen CC; Luo JC; Bair MJ; Chen PY; Chou CK; Fang YJ; Chen MJ; Chen CC; Lee JY; Yang TH; Yu CC; Kuo CC; Chiu MC; Chen CY; Shun CT; Hu WH; Tsai MH; Hsu YC; Tseng CH; Chang CY; Lin JT; El-Omar EM; Wu MS;
    Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):228-241. PubMed ID: 36549320
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison Between Sequential Therapy and Modified Bismuth-Included Quadruple Therapy for Helicobacter pylori Eradication in Chinese Patients.
    Yang X; Tan P; Song L; Lu Z
    Am J Ther; 2016; 23(6):e1436-e1441. PubMed ID: 25923229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial.
    Suo B; Tian X; Zhang H; Lu H; Li C; Zhang Y; Ren X; Yao X; Zhou L; Song Z
    Chin Med J (Engl); 2023 Apr; 136(8):933-940. PubMed ID: 37010246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative study of allicin-containing quadruple therapy vs. bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: a prospective randomized study.
    Li H; Xia XJ; Zhang LF; Chi JS; Liu P; Wu H; Xie XR; Tian DL; Kun KX; Gong RJ; Liu XM; Xu CX
    Eur J Gastroenterol Hepatol; 2021 Feb; 32(2):194-200. PubMed ID: 32804837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of two different dosages of levofloxacin in curing Helicobacter pylori infection: A Prospective, Single-Center, randomized clinical trial.
    Gan HY; Peng TL; Huang YM; Su KH; Zhao LL; Yao LY; Yang RJ
    Sci Rep; 2018 Jun; 8(1):9045. PubMed ID: 29899426
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of furazolidone- and amoxicillin-based quadruple therapy for
    Zhang YW; Hu WL; Cai Y; Zheng WF; Du Q; Kim JJ; Kao JY; Dai N; Si JM
    World J Gastroenterol; 2018 Oct; 24(40):4596-4605. PubMed ID: 30386109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of tegoprazan-based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: A randomized, double-blind, active-controlled study.
    Kim JS; Ko W; Chung JW; Kim TH
    Helicobacter; 2023 Jun; 28(3):e12977. PubMed ID: 37083222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced symptoms and need for antisecretory therapy in veterans 3 years after Helicobacter pylori eradication with ranitidine bismuth citrate/amoxicillin/clarithromycin.
    Sontag SJ; O'Connell S; Schnell T; Chejfec G; Seidel J; Sonnenberg A
    Am J Gastroenterol; 2001 May; 96(5):1390-5. PubMed ID: 11374672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
    Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
    World J Gastroenterol; 2015 Jul; 21(26):8132-9. PubMed ID: 26185386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. One-week regimens containing ranitidine bismuth citrate, furazolidone and either amoxicillin or tetracycline effectively eradicate Helicobacter pylori: a multicentre, randomized, double-blind study.
    Lu H; Zhang DZ; Hu PJ; Li ZS; Lu XH; Fang XC; Xiao SD
    Aliment Pharmacol Ther; 2001 Dec; 15(12):1975-9. PubMed ID: 11736729
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Two-week bismuth-containing quadruple therapy and concomitant therapy are effective first-line treatments for
    Kim SJ; Chung JW; Woo HS; Kim SY; Kim JH; Kim YJ; Kim KO; Kwon KA; Park DK
    World J Gastroenterol; 2019 Dec; 25(46):6790-6798. PubMed ID: 31857780
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New bismuth-containing quadruple therapy in patients infected with Helicobacter pylori: A first Italian experience in clinical practice.
    Tursi A; Di Mario F; Franceschi M; De Bastiani R; Elisei W; Baldassarre G; Ferronato A; Grillo S; Landi S; Zamparella M; De Polo M; Boscariolo L; Picchio M
    Helicobacter; 2017 Jun; 22(3):. PubMed ID: 28125857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
    Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
    Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Furazolidone-based triple and quadruple eradication therapy for Helicobacter pylori infection.
    Xie Y; Zhu Y; Zhou H; Lu ZF; Yang Z; Shu X; Guo XB; Fan HZ; Tang JH; Zeng XP; Wen JB; Li XQ; He XX; Ma JH; Liu DS; Huang CB; Xu NJ; Wang NR; Lu NH
    World J Gastroenterol; 2014 Aug; 20(32):11415-21. PubMed ID: 25170230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of a semi-automatic, intensive follow-up for improving efficacy and adherence of Helicobacter pylori eradication therapy: A randomized controlled trial.
    Chen Y; Yuan H; Ye H; Shi Z; Deng X; Zhang X; Hou X
    Microbiologyopen; 2021 Jan; 10(1):e1172. PubMed ID: 33650799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial.
    Kim YI; Lee JY; Kim CG; Park B; Park JY; Choi IJ
    BMC Gastroenterol; 2021 Mar; 21(1):95. PubMed ID: 33653284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of 7- and 14-Day Eradication Therapy for
    Kim TH; Park JM; Cheung DY; Oh JH
    J Korean Med Sci; 2020 Feb; 35(5):e33. PubMed ID: 32030921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multicenter, randomized, prospective study of 14-day ranitidine bismuth citrate- vs. lansoprazole-based triple therapy for the eradication of Helicobacter pylori in dyspeptic patients.
    Avşar E; Tiftikçi A; Poturoğlu S; Erzin Y; Kocakaya O; Dinçer D; Yıldırım B; Güliter S; Türkay C; Yılmaz U; Onuk MD; Bölükbaş C; Ellidokuz E; Bektaş A; Taşan G; Aytuğ N; Ateş Y; Kaymakoğlu S
    Turk J Gastroenterol; 2013; 24(4):316-21. PubMed ID: 24254262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Colloidal bismuth pectin: an alternative to bismuth subcitrate for the treatment of Helicobacter pylori--positive duodenal ulcer.
    Nie Y; Li Y; Wu H; Sha W; Du H; Dai S; Wang H; Li Q
    Helicobacter; 1999 Jun; 4(2):128-34. PubMed ID: 10382127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.